Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Non-Small-Cell Lung × Digoxin × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Liver Cirrhosis 1 Leiomyosarcoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Malignancies 1 Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 227 Carboplatin 199 Pemetrexed 167 Cisplatin 118 Paclitaxel 107 Nivolumab 88 durvalumab 75 osimertinib 71 Docetaxel 69 Specimen Handling 54 atezolizumab 49 Magnetic Resonance Spectroscopy 48 Drug Therapy 47 Gemcitabine 44 Radiotherapy 41 Bevacizumab 36 Radiosurgery 35 cemiplimab 33 Ipilimumab 33 130-nm albumin-bound paclitaxel 32 tislelizumab 31 Cetuximab 23 Taxes 20 Immunotherapy 20 Immune Checkpoint Inhibitors 20 amivantamab 18 Platinum Compounds 18 Blood Specimen Collection 17 Biopsy 17 Surgical Procedures, Operative 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06575933 2026-02-11

MK-1084-009

Merck Sharp & Dohme LLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡